Skip to Content
Merck
  • Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases.

Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases.

Bioorganic & medicinal chemistry letters (2006-06-01)
Zhiqin Ji, Asma A Ahmed, Daniel H Albert, Jennifer J Bouska, Peter F Bousquet, George A Cunha, Keith B Glaser, Jun Guo, Junling Li, Patrick A Marcotte, Maria D Moskey, Lori J Pease, Kent D Stewart, Melinda Yates, Steven K Davidsen, Michael R Michaelides
ABSTRACT

A series of isothiazolopyrimidines and isoxazolopyrimidines were synthesized and identified as potent KDR inhibitors. SAR studies led to isothiazolopyrimidine urea analogs that potently inhibit VEGFR tyrosine kinases (KDR enzymatic and cellular IC(50) values below 10 nM) as well as cKIT and TIE2. The selected compounds 8 and 13 display 56% and 48% oral bioavailability in mice, respectively.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
2-Fluoro-5-(trifluoromethyl)phenyl isocyanate, 97%